YH002
2020.06.30
Drug : YH002(OX40)
Progress : Phase I clinical trial
Indication : Solid tumor
Country/Region : Australia
Study Title : A First-in-Human (FIH), Multicenter, Open-Label, Phase 1 Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of YH002 in Subjects with Advanced Solid MalignanciesLink to Trial : https://clinicaltrials.gov/ct2/show/NCT04353102
More information
Eucure (Beijing) Biopharma Co., Ltd.
23F, Tower 3, China Central Place, No.77, Jian Guo Road, Chaoyang District, Beijing, P. R. China,100025
WeChat
2020 Eucure & Biocytogen京ICP备18006768号-1